Corvus Pharmaceuticals (CRVS) Jefferies Global Healthcare Conference 2026 summary

Key data, scientific, and clinical insights

• Soquelitinib is a first-in-class, highly selective oral ITK inhibitor with broad potential in immune diseases, currently in phase II for atopic dermatitis and phase III for peripheral T-cell lymphoma (PTCL).

• The drug blocks Th2 and Th17 cytokines, increases Tregs, and rebalances immunity, offering a mechanism distinct from current therapies and supporting durable responses and disease modification.

• Phase I atopic dermatitis trial showed dose-dependent efficacy, with up to 75% achieving EASI-75 and 33% achieving IGA 0/1 after 8 weeks; responses were maintained post-treatment with no rebound.

• Efficacy was consistent in patients with prior systemic therapy, including those resistant to other treatments.

• Safety profile is clean, with no serious adverse events or significant lab abnormalities reported across hundreds of patients.

Pipeline, development plans, and milestones

• Ongoing phase III trial in lymphoma with interim data expected late this year and final data in the second half of 2027.

• Phase II atopic dermatitis trial is enrolling, targeting 200 patients with multiple dosing arms and 12 weeks of therapy; data expected in Q3 2027.

• Additional phase II studies in asthma and hidradenitis suppurativa are planned to start in the second half of 2026.

• Collaboration with Angel Pharmaceuticals in China is underway, with complementary trials and data expected by late 2026.

• Multiple value-driving milestones are expected through 2026, including interim analyses and data readouts for key indications.

Mechanistic and market positioning

• Soquelitinib’s selectivity for ITK, sparing RLK, is designed to minimize off-target effects and maximize safety.

• The drug’s mechanism allows for broad application across Th2 and Th17-driven diseases, including atopic dermatitis, asthma, psoriasis, and fibrotic diseases.

• Market for advanced therapies in these indications is projected to reach $170 billion by 2030, with oral agents representing a significant growth opportunity.

• Biomarker data confirm persistent reduction in Th2 cytokines (IL-4, IL-5, IL-13, TARC) and increase in Tregs, supporting durable clinical responses.

• Upregulation of SOCS3 and selective reduction of STAT6 and JAK1 in T cells further validate the drug’s targeted immunomodulatory effects.